Emile Andriambeloson (left) is President and Head of Research at NEUROFIT (Illkirch, France). NEUROFIT is a preclinical contract research organization that provides clients with animal models to evaluate treatments, particularly for neurodegenerative and psychiatric disorders. Semaglutide, a glucagon-like peptide-1 receptor (GLP-1) agonist sold under brand names Ozempic and Wegovy, is used to treat type 2 diabetes and obesity.